Start a GLP-1 Receptor Agonist
For a patient with type 2 diabetes and A1c 6.9% who cannot tolerate metformin due to GI side effects, initiate a GLP-1 receptor agonist as first-line therapy. This provides excellent glycemic control without hypoglycemia risk, promotes weight loss, and offers cardiovascular benefits 1, 2.
Rationale for GLP-1 RA Selection
The most recent AACE 2023 guidelines explicitly recommend GLP-1 RAs as preferred agents when metformin is not appropriate 1. With an A1c of 6.9%, this patient is only 0.4% above the typical target of 6.5%, making a single potent agent reasonable rather than combination therapy 1, 2.
Why Not Other Options?
- SGLT2 inhibitors: Also acceptable as monotherapy, but GLP-1 RAs demonstrate superior A1c reduction (typically 1.0-1.5% vs 0.5-1.0% for SGLT2i) 2, 3
- DPP-4 inhibitors: Less potent than GLP-1 RAs, reducing A1c by only 0.5-0.8% 4
- Sulfonylureas: Cause hypoglycemia and weight gain—inappropriate for a patient near target 4
- Thiazolidinediones: Associated with weight gain, fluid retention, and fracture risk 5
Specific GLP-1 RA Recommendations
Preferred agents with cardiovascular outcome benefits 1, 2:
- Semaglutide (subcutaneous 0.5-1.0 mg weekly or oral 7-14 mg daily)
- Dulaglutide (0.75-1.5 mg weekly)
- Liraglutide (1.2-1.8 mg daily)
Start with the lowest dose and titrate up over 4-8 weeks to minimize GI side effects 4, 2. While GLP-1 RAs can cause nausea and diarrhea initially, these symptoms typically resolve within 2-4 weeks and are generally milder than metformin-induced diarrhea 6.
Alternative: SGLT2 Inhibitor
If the patient has cardiovascular disease, heart failure, or chronic kidney disease (even if not yet apparent), an SGLT2 inhibitor would be equally appropriate as first-line therapy 1, 2. These agents provide:
- Cardiovascular mortality reduction (12-26% risk reduction) 7
- Heart failure hospitalization reduction (18-25%) 7
- Kidney disease progression reduction (24-39%) 7
Preferred SGLT2i agents: empagliflozin 10-25 mg daily, canagliflozin 100-300 mg daily, or dapagliflozin 5-10 mg daily 1, 4.
Critical Monitoring Points
Before initiating therapy, assess:
- Kidney function (eGFR) - important for both GLP-1 RA and SGLT2i dosing 2
- Cardiovascular disease history - influences agent selection 1
- Weight and BMI - both drug classes promote weight loss 2, 7
Common pitfall to avoid: Do not restart metformin or add a DPP-4 inhibitor to a GLP-1 RA, as this provides no additional benefit and increases cost and pill burden 2.
If Monotherapy Insufficient
Should A1c remain above target after 3 months on optimized GLP-1 RA monotherapy, add an SGLT2 inhibitor to create a potent, complementary combination that addresses multiple pathophysiologic defects without hypoglycemia risk 1, 2, 3. This combination achieves target A1c in 86-88% of patients 8, 3.